Quality of RecoveryPhase 4NCT05040022
Quality of Recovery Under Low or Standard Pneumoperitoneum Pressure
A Phase 4 study testing Pneumoperitoneum pressure 10 mmHg and Pneumoperitoneum pressure 14 mmHg in people with Quality of Recovery and Postoperative Pain, run by Pontificia Universidade Catolica de Sao Paulo at 1 site in Brazil.
Trial summary
The use of low-pressure pneumoperitoneum seems to be able to reduce complications such as postoperative pain. However, the quality of evidence for most studies evaluating this relationship is considered low. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Quality of Recovery, Postoperative Pain, Postoperative Nausea and Vomiting
- What is being tested?
- Pneumoperitoneum pressure 10 mmHg and Pneumoperitoneum pressure 14 mmHg
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteBrazil
- Study dates
- 1 Oct 2021to 15 Jan 2022
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Physical status I and II according to the American Society of Anesthesiologists (ASA)
- Undergoing elective laparoscopic cholecystectomy
Who cannot join
- refuse to participate
- Present inability to communicate due to altered level of consciousness or due to the presence of neurological or psychiatric illness
- Present contraindication to the use of any of the drugs employed in the study
- Present history of alcohol or drug addiction
- Body mass index (BMI) ≥ 35
- Presence of chronic pain or use of opioids.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Quality of Recovery After Laparoscopic Cholecystectomy Under Moderate Neuromuscular Blockade Using Low Pressure or Standard Pneumoperitoneum Pressure
The use of low-pressure pneumoperitoneum seems to be able to reduce complications such as postoperative pain. However, the quality of evidence for most studies evaluating this relationship is considered low. The absence of concealment of pneumoperitoneum pressure and the lack of description of neuromuscular blockade characteristics are the main causes of bias. The purpose of this study will be to evaluate by means of a prospective, randomized and double-blinded trial, the quality of recovery (QoR-15) questionnaire of patients undergoing laparoscopic cholecystectomy under moderate neuromuscular blockade, using low pneumoperitoneum pressure or "standard" pressure. Eighty patients submitted to laparoscopic cholecystectomy and randomly distributed in two groups will be included: low pneumoperitoneum pressure (10 mmHg) or "standard" pressure (14 mmHg). The value of abdominal pressure will be kept hidden for all participants, except for the nurse responsible for the operating room. Moderate neuromuscular blockade will be maintained according to Train-of-four count (TOFc) = 3 for all cases.
Read the detailed description
METHODS After obtaining approval from the Research Ethics Committee of the Faculty of Medical and Health Sciences of PUC-SP on August 10th 2021, CAAE 49753621.1.0000.5373, patients 18 to 70 years of age, with physical status I and II according to the American Society of Anesthesiologists (ASA), undergoing elective laparoscopic cholecystectomy at Hospital Santa Lucinda will be evaluated for participation in this clinical, prospective, and randomized clinical trial. Patients will be excluded before randomization if: (i) refuse to participate; (ii) present inability to communicate due to altered level of consciousness or due to the presence of neurological or psychiatric illness; (iii) present contraindication to the use of any of the drugs employed in the study; (iv) present history of alcohol or drug addiction; (v) body mass index (BMI) ≥ 35; (vi) and the presence of chronic pain or use of opioids.
Study sequence
Patients will be randomized according to the sequence of random numbers generated by a computer using a specific program (www.random.org). For each patient, an opaque envelope containing the group to which the patient will be allocated will be prepared, sealed, and numbered sequentially. On the day of the surgery, after the pre-anesthetic evaluation and the necessary explanation about the study, study consent will be obtained. Age, gender, physical status, body mass index (BMI) and risk classification for post-operative nausea and vomiting (PONV) will be recorded as proposed by Apfel et al. All patients will be instructed on the numerical scale of post-operative pain and on the QoR-15 questionnaire. No pre-anesthetic medication will be administered.
Anaesthesia and surgery After entering the operating room, all patients will be monitored with ASA standard monitoring. NMB will be assessed using acceleromyography (TOF Watch SX®; Schering-Plow) as recommended for use in clinical research. The acceleration transducer will be attached to the volar side in the distal phalanx of the thumb. Anaesthesia will be induced using 0.5 µg/kg remifentanil for 3 minutes, followed by propofol (2 mg/kg), and rocuronium (0.3 mg/Kg). After tracheal intubation anesthesia will be maintained with 1.5%-3% sevoflurane and 0.1-0.5 µg/kg/min remifentanil, both necessary to maintain an adequate anesthesia plane. The ventilation will be controlled with the tidal volume and respiratory rate adjusted aiming for an end-tidal CO2 between 30 and 40 mmHg. Additional doses of rocuronium (0.05 mg/kg) will be administered to maintain TOFc = 3 until gallbladder removal. TOF stimulation will be applied every 15 minutes and the time under moderate or deep NMB will be registered. Hydration will be achieved using lactated Ringer's solution (500 ml in the first 30 minutes followed by 2 ml/kg/h maintenance). All patients will receive dexamethasone (8 mg) and ketoprofen (100 mg) at the beginning of the surgery and ondansetron (4 mg) 15 minutes before the end of the procedure. Atropine (0.02 mg/kg) and neostigmine (0.05 mg/kg) will be administered to obtain T4/T1 > 0.9 and, after awakening, extubation will be performed. The time elapsed between the discontinuation of the anesthetic agents and awakening will be recorded. Furthermore, the duration of the surgery and the total dose of rocuronium will be noted. Local anesthetic infiltration of the trocar insertion sites will be performed by the surgical team using 20 ml of 0.75% ropivacaine under direct visualization, and included the aponeurosis, the subcutaneous tissue, and the skin. The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10) or 14 mmHg (group 14). The display of the insufflation pressure value was blinded to the surgical team and the anesthesiologist, but not the operating room nurse. At the end of surgery, irrigation of the abdominal cavity and the surgical site will be performed using saline solution. The pneumoperitoneum will be completely decompressed in all patients using manual compression. Surgery will be performed by the same surgical team comprised of two experienced laparoscopists and two resident clinicians. At the end of the procedure, the surgical team will be asked to classify the surgical conditions (good visualization, adequate working space) using a 5-point Likert scale of 'very bad' (1) to 'excellent' (5). The patients will be transferred to the PACU and monitored until the criterion for discharge were met (score according to the Aldrete and Kroulik modified scale = 10). During the PACU stay, the magnitude of pain, nausea, vomiting, and PACU length of stay will be documented. Pain will be evaluated every 15 minutes using a verbal numeric scale (VNS) of 0-10, where 0 was 'no pain' and 10 the 'most severe pain imaginable'. Intravenous morphine will be administered every 5 minutes to obtain a score <3 (2 mg for pain <7 and 3 mg for pain ≥7). PONV will be treated with intravenous dimenhydrinate 30 mg. Following PACU discharge to the ward, patients will receive 100 mg of ketoprofen every 12 hours and 1 g of dipyrone every 6 hours intravenously. Whenever the patient considers the analgesic regimen to be insufficient, tramadol 100 mg will be administered orally at intervals of up to 8 hours. In case of nausea and/or vomiting, ondansetron 8 mg will be administered intravenously. Pain intensity (VNS) will be recorded at 4, 8, 12 and 24 hours after arrival on the ward. Tramadol utilization as well as the occurrence of nausea, vomiting and other complications will be documented. As per institutional protocol, all study patients remain in hospital for a period of 24 hours.
Questionnaire QoR-15 The interviews will be conducted: immediately after opening the envelope that will define the group in which the patient will be included. The preoperative questionnaire (QoR-15) will be applied by a physician of the residency program in anesthesiology and, after surgery, by one of three medical students, unrelated to the anesthetic procedure performed. The QoR-15 has 15 questions divided into 5 dimensions: emotional state, physical comfort, psychological support, physical independence and pain. Each question should generate a score based on a numerical scale of 11 points (zero to 10), totaling zero (poor recovery) up to 10 (excellent recovery).
Statistical analysis The sample size was calculated considering a power of 90% to detect a difference of 8 points in the QoR-15, which indicates the need to include 35 participants in each group. Considering possible losses, the final sample will include 80 patients.
- Conditions
- Quality of Recovery, Postoperative Pain, Postoperative Nausea and Vomiting, Neuromuscular Blockade
- Being tested
- Pneumoperitoneum pressure 10 mmHg, Pneumoperitoneum pressure 14 mmHg
- Medical subject headings
- Pain, Postoperative, Postoperative Nausea and Vomiting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pneumoperitoneum pressure 10 mmHgDrug
The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
Pneumoperitoneum pressure 14 mmHgDrug
The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
| Study group | Role | What they receive |
|---|---|---|
| Group pneumoperitoneum pressure 10 | Active comparator | Pneumoperitoneum pressure at 10 mmHg Receives: Drug: Pneumoperitoneum pressure 10 mmHg |
| Group neumoperitoneum pressure 14 | Placebo comparator | Pneumoperitoneum pressure at 10 mmHg Receives: Drug: Pneumoperitoneum pressure 14 mmHg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of recovery
The quality of recovery will be assessed using the Qualtity of Recovery 15
questionnaire. Total scores range from 0 to 150. Higher scores mean a better outcome.
Measured: From randomization up to 15 days
Secondary outcomes (1)
Postoperative pain
Pain intensity (Verbal Numeric Scale) will be assessed at 15, 30, 45 and 60 minutes during postanesthetic unit (PACU) stay and 4, 8, 12 and 24 hours after arrival on the ward.Verbal Numeric Scale scores range from 0 to 10. Higher scores mean a worse outcome.
Measured: From the PACU arriving up to 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2021
- Study start1 Oct 2021 (estimated)
- Primary completion5 Jan 2022 (estimated)
- Study completion15 Jan 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Quality of RecoveryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, randomized and double-blinded
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pontificia Universidade Catolica de Sao Paulo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eduardo Toshiyuki Moro, Pontificia Universidade Catolica de Sao Paulo
- Investigators
- Eduardo Moro, Principal investigator, Faculdade de Ciências Médicas e da Saúde PUCSP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05040022
- Sponsor's protocol ID
- CAAE 49753621.1.0000.5373
- Status last verified
- Sep 2021
- First submitted
- 2 Sep 2021
- Last updated
- 20 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Results will be submitted to publication
Study at a glance
From the registry record, last updated by the sponsor on 20 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quality of Recovery After Laparoscopic Cholecystectomy Under Moderate Neuromuscular Blockade Using Low Pressure or Standard Pneumoperitoneum Pressure
- ClinicalTrials.gov ID
- NCT05040022
- Acronym / sponsor ID
- CAAE 49753621.1.0000.5373
- Conditions
- Quality of Recovery, Postoperative Pain, Postoperative Nausea and Vomiting, Neuromuscular Blockade
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Pontificia Universidade Catolica de Sao PauloUniversity, hospital or other
- Study start
- 1 Oct 2021 (estimated)
- Primary completion
- 5 Jan 2022 (estimated)
- Study completion
- 15 Jan 2022 (estimated)
- First posted
- 10 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The use of low-pressure pneumoperitoneum seems to be able to reduce complications such as postoperative pain. However, the quality of evidence for most studies evaluating this relationship is considered low. The absence of concealment of pneumoperitoneum pressure and the lack of description of neuromuscular blockade characteristics are the main causes of bias. The purpose of this study will be to evaluate by means of a prospective, randomized and double-blinded trial, the quality of recovery (QoR-15) questionnaire of patients undergoing laparoscopic cholecystectomy under moderate neuromuscular blockade, using low pneumoperitoneum pressure or "standard" pressure. Eighty patients submitted to laparoscopic cholecystectomy and randomly distributed in two groups will be included: low pneumoperitoneum pressure (10 mmHg) or "standard" pressure (14 mmHg). The value of abdominal pressure will be kept hidden for all participants, except for the nurse responsible for the operating room. Moderate neuromuscular blockade will be maintained according to Train-of-four count (TOFc) = 3 for all cases.
Detailed description
METHODS After obtaining approval from the Research Ethics Committee of the Faculty of Medical and Health Sciences of PUC-SP on August 10th 2021, CAAE 49753621.1.0000.5373, patients 18 to 70 years of age, with physical status I and II according to the American Society of Anesthesiologists (ASA), undergoing elective laparoscopic cholecystectomy at Hospital Santa Lucinda will be evaluated for participation in this clinical, prospective, and randomized clinical trial. Patients will be excluded before randomization if: (i) refuse to participate; (ii) present inability to communicate due to altered level of consciousness or due to the presence of neurological or psychiatric illness; (iii) present contraindication to the use of any of the drugs employed in the study; (iv) present history of alcohol or drug addiction; (v) body mass index (BMI) ≥ 35; (vi) and the presence of chronic pain or use of opioids.
Study sequence
Patients will be randomized according to the sequence of random numbers generated by a computer using a specific program (www.random.org). For each patient, an opaque envelope containing the group to which the patient will be allocated will be prepared, sealed, and numbered sequentially. On the day of the surgery, after the pre-anesthetic evaluation and the necessary explanation about the study, study consent will be obtained. Age, gender, physical status, body mass index (BMI) and risk classification for post-operative nausea and vomiting (PONV) will be recorded as proposed by Apfel et al. All patients will be instructed on the numerical scale of post-operative pain and on the QoR-15 questionnaire. No pre-anesthetic medication will be administered.
Anaesthesia and surgery After entering the operating room, all patients will be monitored with ASA standard monitoring. NMB will be assessed using acceleromyography (TOF Watch SX®; Schering-Plow) as recommended for use in clinical research. The acceleration transducer will be attached to the volar side in the distal phalanx of the thumb. Anaesthesia will be induced using 0.5 µg/kg remifentanil for 3 minutes, followed by propofol (2 mg/kg), and rocuronium (0.3 mg/Kg). After tracheal intubation anesthesia will be maintained with 1.5%-3% sevoflurane and 0.1-0.5 µg/kg/min remifentanil, both necessary to maintain an adequate anesthesia plane. The ventilation will be controlled with the tidal volume and respiratory rate adjusted aiming for an end-tidal CO2 between 30 and 40 mmHg. Additional doses of rocuronium (0.05 mg/kg) will be administered to maintain TOFc = 3 until gallbladder removal. TOF stimulation will be applied every 15 minutes and the time under moderate or deep NMB will be registered. Hydration will be achieved using lactated Ringer's solution (500 ml in the first 30 minutes followed by 2 ml/kg/h maintenance). All patients will receive dexamethasone (8 mg) and ketoprofen (100 mg) at the beginning of the surgery and ondansetron (4 mg) 15 minutes before the end of the procedure. Atropine (0.02 mg/kg) and neostigmine (0.05 mg/kg) will be administered to obtain T4/T1 > 0.9 and, after awakening, extubation will be performed. The time elapsed between the discontinuation of the anesthetic agents and awakening will be recorded. Furthermore, the duration of the surgery and the total dose of rocuronium will be noted. Local anesthetic infiltration of the trocar insertion sites will be performed by the surgical team using 20 ml of 0.75% ropivacaine under direct visualization, and included the aponeurosis, the subcutaneous tissue, and the skin. The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10) or 14 mmHg (group 14). The display of the insufflation pressure value was blinded to the surgical team and the anesthesiologist, but not the operating room nurse. At the end of surgery, irrigation of the abdominal cavity and the surgical site will be performed using saline solution. The pneumoperitoneum will be completely decompressed in all patients using manual compression. Surgery will be performed by the same surgical team comprised of two experienced laparoscopists and two resident clinicians. At the end of the procedure, the surgical team will be asked to classify the surgical conditions (good visualization, adequate working space) using a 5-point Likert scale of 'very bad' (1) to 'excellent' (5). The patients will be transferred to the PACU and monitored until the criterion for discharge were met (score according to the Aldrete and Kroulik modified scale = 10). During the PACU stay, the magnitude of pain, nausea, vomiting, and PACU length of stay will be documented. Pain will be evaluated every 15 minutes using a verbal numeric scale (VNS) of 0-10, where 0 was 'no pain' and 10 the 'most severe pain imaginable'. Intravenous morphine will be administered every 5 minutes to obtain a score <3 (2 mg for pain <7 and 3 mg for pain ≥7). PONV will be treated with intravenous dimenhydrinate 30 mg. Following PACU discharge to the ward, patients will receive 100 mg of ketoprofen every 12 hours and 1 g of dipyrone every 6 hours intravenously. Whenever the patient considers the analgesic regimen to be insufficient, tramadol 100 mg will be administered orally at intervals of up to 8 hours. In case of nausea and/or vomiting, ondansetron 8 mg will be administered intravenously. Pain intensity (VNS) will be recorded at 4, 8, 12 and 24 hours after arrival on the ward. Tramadol utilization as well as the occurrence of nausea, vomiting and other complications will be documented. As per institutional protocol, all study patients remain in hospital for a period of 24 hours.
Questionnaire QoR-15 The interviews will be conducted: immediately after opening the envelope that will define the group in which the patient will be included. The preoperative questionnaire (QoR-15) will be applied by a physician of the residency program in anesthesiology and, after surgery, by one of three medical students, unrelated to the anesthetic procedure performed. The QoR-15 has 15 questions divided into 5 dimensions: emotional state, physical comfort, psychological support, physical independence and pain. Each question should generate a score based on a numerical scale of 11 points (zero to 10), totaling zero (poor recovery) up to 10 (excellent recovery).
Statistical analysis The sample size was calculated considering a power of 90% to detect a difference of 8 points in the QoR-15, which indicates the need to include 35 participants in each group. Considering possible losses, the final sample will include 80 patients.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Prospective, randomized and double-blinded
| Arm | Type | Receives |
|---|---|---|
| Group pneumoperitoneum pressure 10 | Active comparator | Drug: Pneumoperitoneum pressure 10 mmHgPneumoperitoneum pressure at 10 mmHg |
| Group neumoperitoneum pressure 14 | Placebo comparator | Drug: Pneumoperitoneum pressure 14 mmHgPneumoperitoneum pressure at 10 mmHg |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Physical status I and II according to the American Society of Anesthesiologists (ASA)
- Undergoing elective laparoscopic cholecystectomy
Key exclusion criteria (6 listed)
- refuse to participate
- Present inability to communicate due to altered level of consciousness or due to the presence of neurological or psychiatric illness
- Present contraindication to the use of any of the drugs employed in the study
- Present history of alcohol or drug addiction
- Body mass index (BMI) ≥ 35
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pneumoperitoneum pressure 10 mmHgThe abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10) | Drug | Group pneumoperitoneum pressure 10 |
| Pneumoperitoneum pressure 14 mmHgThe abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14). | Drug | Group neumoperitoneum pressure 14 |
Primary outcome
Quality of recovery
Time frame: From randomization up to 15 days
The quality of recovery will be assessed using the Qualtity of Recovery 15 questionnaire. Total scores range from 0 to 150. Higher scores mean a better outcome.
1 secondary outcome
Postoperative pain
Time frame: From the PACU arriving up to 24 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Sep 2021.
- Individual participant dataSharing planned: Yes. Results will be submitted to publication
Related trials for Quality of Recovery
Recruiting
ITPB 1 vs 3 in VATS
Musculoskeletal Diseases or Conditions
Not yet recruiting
Tizanidine Premedication Versus Placebo for Laryngeal Mask Airway Insertion and Recovery in Adults Undergoing Ambulatory Surgery
Airway Management
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Not yet recruiting
Esketamine Combined With Transcutaneous Electrical Acupoint Stimulation on Postoperative Recovery Quality After Elective Cesarean Section
Cesarean Section (MeSH: D002585), Postoperative Pain After Cesarean Section
Not yet recruiting
Segmental Thoracic vs Lumbar Spinal: Recovery After Elective Cesarean
Cesarean
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eduardo Moro principal investigator
Faculdade de Ciências Médicas e da Saúde PUCSP
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Pneumoperitoneum pressure 10 mmHg and Pneumoperitoneum pressure 14 mmHg in people with Quality of Recovery and Postoperative Pain, run by Pontificia Universidade Catolica de Sao Paulo at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Eduardo Moro (15997728015, edumoro85@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of recovery (time frame: From randomization up to 15 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Sep 2021.